Nexalin Technology, Inc. (NXL)
NASDAQ: NXL · Real-Time Price · USD
0.4298
-0.0012 (-0.28%)
At close: Apr 14, 2026, 4:00 PM EDT
0.4100
-0.0198 (-4.61%)
After-hours: Apr 14, 2026, 7:55 PM EDT
Nexalin Technology Revenue
In the year 2025, Nexalin Technology had annual revenue of $301.65K with 78.78% growth. Nexalin Technology had revenue of $171.90K in the quarter ending December 31, 2025, with 532.46% growth.
Revenue (ttm)
$301.65K
Revenue Growth
+78.78%
P/S Ratio
29.33
Revenue / Employee
$50,275
Employees
6
Market Cap
8.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 301.65K | 132.93K | 78.78% |
| Dec 31, 2024 | 168.72K | 57.97K | 52.35% |
| Dec 31, 2023 | 110.75K | -1.21M | -91.62% |
| Dec 31, 2022 | 1.32M | 1.18M | 817.20% |
| Dec 31, 2021 | 144.07K | -98.85K | -40.69% |
| Dec 31, 2020 | 242.91K | 35.53K | 17.13% |
| Dec 31, 2019 | 207.38K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Trinity Biotech | 48.57M |
| Vivos Therapeutics | 17.32M |
| Beyond Air | 6.92M |
| Biomerica | 4.46M |
| Tenon Medical | 3.94M |
| Intelligent Bio Solutions | 3.58M |
| Sintx Technologies | 1.02M |
| Co-Diagnostics | 622.49K |
NXL News
- 19 hours ago - Join Nexalin's Exclusive Live Investor Webinar and Q&A Session on April 21 - GlobeNewsWire
- 5 days ago - Nexalin Announces Peer-Reviewed Study Showing the Company's DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents - GlobeNewsWire
- 7 weeks ago - Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia Market - GlobeNewsWire
- 7 weeks ago - Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological Disorders - GlobeNewsWire
- 2 months ago - Nexalin Launches NeuroCare®, an AI-Driven Virtual Clinic Designed to Transform Access for Patients with Alzheimer's, Mood Disorders, TBI & PTSD Care - GlobeNewsWire
- 2 months ago - Nexalin Highlights its Expanding Body of Peer-Reviewed Neuroimaging Research Confirming its DIFS™ Technology as the Leader in Evidenced-Based Non-Invasive Brain Stimulation - GlobeNewsWire
- 3 months ago - Published Peer-Reviewed Study Demonstrates Nexalin's DIFS™ Neurostimulation Improves Attention and Normalizes Brain Activity in Patients with ADHD - GlobeNewsWire
- 4 months ago - Nexalin Technology Completes FDA Q-Submission Meeting for Gen-2 SYNC™ Neurostimulation Console in Alzheimer's Disease Program - GlobeNewsWire